Economic evaluation in the field of mental health: conceptual basis.

OBJECTIVE Technological advances in medicine have given rise to a dilemma concerning the use of new health technologies in a context of limited financial resources. In the field of psychiatry, health economic evaluation is a recent method that can assist in choosing interventions with different cost and/or effectiveness for specific populations or conditions. This article introduces clinicians to the fundamental concepts required for critical assessment of health economic evaluations. METHODS The authors conducted a review with systematic methods to assess the essential theoretical framework of health economic evaluation and mental health in Brazil through textbooks and studies indexed in the PubMed, Cochrane Central, LILACS, NHS CRD, and REBRATS databases. A total of 334 studies were found using the specified terms (MeSH - Mental Health AND Economic, Medical) and filters (Brazil AND Humans); however, only five Brazilian economic evaluations were found. RESULTS AND CONCLUSIONS Economic evaluation studies are growing exponentially in the medical literature. Publications focusing on health economics as applied to psychiatry are increasingly common, but Brazilian data are still very incipient. In a country where financial resources are so scarce, economic analyses are necessary to ensure better use of public resources and wider population access to effective health technologies.

[1]  Aman Khan [Cost analysis]. , 2022, ZWR.

[2]  C. Asseburg,et al.  Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model , 2012, PloS one.

[3]  Morgan E. Lim,et al.  Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application , 2011, ClinicoEconomics and outcomes research : CEOR.

[4]  M. Ferraz,et al.  Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. , 2011, Revista de saude publica.

[5]  J. Brazier,et al.  Estimating the SF-6D value set for a population-based sample of Brazilians. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  M. Ferraz,et al.  Cost-Effectiveness of Home Visits in the Outpatient Treatment of Patients with Alcohol Dependence , 2009, European Addiction Research.

[7]  L. Lindner,et al.  Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. , 2009, Revista de saude publica.

[8]  L. Lindner,et al.  Evaluación económica del tratamiento de la esquizofrenia con antipsicóticos en Sistema Único de Salud , 2009 .

[9]  David McDaid,et al.  Is it worth investing in mental health promotion and prevention of mental illness? A systematic review of the evidence from economic evaluations , 2008, BMC public health.

[10]  L. Salvador-Carulla,et al.  Implementing mental health economic evaluation evidence: Building a bridge between theory and practice , 2007 .

[11]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[12]  M. Drummond,et al.  A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.

[13]  M. Ferraz,et al.  Cost of schizophrenia: direct costs and use of resources in the State of São Paulo. , 2006, Revista de saude publica.

[14]  J. Ayuso-Mateos,et al.  Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder , 2005, British Journal of Psychiatry.

[15]  J. Rehm,et al.  Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. , 2004, Journal of studies on alcohol.

[16]  J. Ayuso-Mateos,et al.  Reducing the global burden of depression , 2004, British Journal of Psychiatry.

[17]  M Sculpher,et al.  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.

[18]  Rob Baltussen,et al.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .

[19]  David McDaid,et al.  Because It's Worth It: A Practical Guide to Conducting Economic Evaluations in the Social Welfare Field , 2003 .

[20]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[21]  D. Feeny,et al.  The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.

[22]  S. Evers,et al.  Economic evaluation of mental health care interventions. A review. , 1997, Health economics.

[23]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[24]  Diana B. Petitti,et al.  Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .

[25]  G W Torrance,et al.  Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials: Two Examples , 1989, Medical care.

[26]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[27]  Julian Perelman Avaliação económica em saúde , 2014 .

[28]  T. Einarson,et al.  The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary , 2012, PharmacoEconomics.

[29]  K. Roberts Foresight mental capital and wellbeing project , 2010 .

[30]  40026386 Return Undeliverable,et al.  Canadian Agency for Drugs and Technologies in Health , 2009 .

[31]  Peter Muennig,et al.  Cost-effectiveness analyses in health : a practical approach , 2008 .

[32]  L. Salvador-Carulla,et al.  Cost-effectiveness and mental health , 2008 .

[33]  M. Severn,et al.  Canadian Agency for Drugs and Technologies in Health Effectiveness of magnetic resonance imaging ( MRI ) screening for women at high risk of breast cancer , 2007 .

[34]  C. Normand,et al.  A systematic review of the role of bisphosphonates in metastatic disease. , 2004, Health technology assessment.

[35]  N. Waugh,et al.  Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. , 2001, Health technology assessment.

[36]  J Beecham,et al.  A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression. , 2000, Health technology assessment.

[37]  R. Koff,et al.  Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine , 1995 .

[38]  Martin Knapp,et al.  Costing psychiatric interventions. , 1992 .

[39]  C. Brewin,et al.  Measuring mental health needs , 1992 .

[40]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[41]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .